azetidine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso-Valenteen, F; Brotherton-Pleiss, C; Celeridad, M; Chen, J; Chen, W; Chen, Y; Cosford, NDP; Fu, W; Kershaw, KM; Limpert, AS; Lopez-Tapia, F; Medina-Kauwe, L; Mikhael, S; Nakamura, K; Pan, S; Sheffler, DJ; Shiao, SL; Tius, MA; Turkson, J; Verma, N; Yue, P; Zhu, Y | 1 |
1 other study(ies) available for azetidine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
Topics: Animals; Apoptosis; Azetidines; Cell Line, Tumor; Humans; Mice; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2022 |